## PrestigeConsumer <br> HEALTHCARE

## Prestige Brands Holdings, Inc. Reports First Quarter Fiscal 2017

August 4, 2016
Revenues Up 9.1\% to \$209.6 Million
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 4, 2016-- Prestige Brands Holdings, Inc. (NYSE:PBH) today announced results for the first quarter of fiscal year 2017, which ended June 30, 2016.

Key first fiscal quarter highlights include:

- Reported revenues increased $9.1 \%$ to $\$ 209.6$ million;
- Net cash provided by operating activities totaled $\$ 50.8$ million;
- Integration of DenTek® acquisition is complete; focus on brand-building continues;
- Entered into an agreement to divest three non-core brands for $\$ 40.0$ million plus inventory and completed the transaction on July 7, 2016.
"We are very pleased with the Company's first quarter financial results," said Ron Lombardi, President and CEO. "With this quarter's strong momentum across many of our key North American and International brands and the addition of revenues from DenTek, we believe we are well-positioned to meet our objectives for the full fiscal year."

Mr. Lombardi continued, "We are also pleased with the progress made in strategic portfolio management on two fronts. First, we completed the integration of the DenTek acquisition into our business. Second, we completed a transaction in early July to divest three non-core brands for approximately $\$ 40$ million in cash. These strategic moves enabled us to continue driving our portfolio mix toward our stated long-term objective of $85 \%$ in invest for growth brands and 15\% in manage for cash brands."

## First Fiscal Quarter Ended June 30, 2016

Reported revenues for the first quarter of fiscal 2017 were $\$ 209.6$ million, an increase of $9.1 \%$ over the prior year comparable quarter's revenues of $\$ 192.1$ million. These results reflect strong consumption levels across the Company's invest for growth brands, which include core over-the-counter (OTC) healthcare brands and our international business, as well as revenues from a full quarter of ownership of DenTek.

Reported net loss for the first quarter of fiscal 2017 totaled $\$ 5.5$ million, or $\$ 0.10$ per share. This included a non-cash after tax charge of $\$ 35.5$ million (net of a tax benefit of $\$ 19.9$ million) related to the divestiture of three non-core brands. Adjusted net income for the first quarter of fiscal 2017 was $\$ 31.4$ million, or $\$ 0.59$ per share, an increase of $14.7 \%$ over the prior year comparable period's adjusted net income of $\$ 27.4$ million, or $\$ 0.52$ per diluted share.

## Free Cash Flow \& Balance Sheet

The Company's Net cash provided by operating activities was $\$ 50.8$ million, while the Non-GAAP Adjusted Free Cash Flow for the first quarter ended June 30 , 2016 was $\$ 50.2$ million compared to the prior year comparable quarter's Net cash provided by operating activities of $\$ 43.5$ million and Non-GAAP Adjusted Free Cash Flow of $\$ 42.7$ million, an increase of $16.6 \%$ and $17.4 \%$, respectively.

The Company's net debt at June 30, 2016 was $\$ 1.6$ billion, reflecting debt repayments of $\$ 50.0$ million during the first fiscal quarter. Proceeds from the divestiture of three non-core brands in July 2016 will be applied to debt repayments in the fiscal second quarter. At June 30, 2016, the Company's covenant-defined leverage ratio was approximately 4.8.

## Segment Review

Reported revenues for the North American OTC Healthcare segment were $\$ 172.1$ million for the first quarter of fiscal 2017, 10.6\% higher than the prior year comparable quarter's revenues of $\$ 155.6$ million. Reported revenues for the International OTC Healthcare segment for the first quarter of fiscal 2017 were $\$ 15.8$ million, $11.0 \%$ higher than the $\$ 14.2$ million reported in the prior year comparable period. Revenues for both the North American OTC Healthcare segment and the International OTC Healthcare segment were impacted by increased consumption levels as well as revenues from DenTek for three months. Reported revenues for the Household Cleaning segment were $\$ 21.7$ million for the first quarter of fiscal 2017, a decrease of $2.6 \%$ over the prior year comparable quarter's revenues of $\$ 22.3$ million.

## Outlook

Mr. Lombardi said, "To reflect the divestiture of the three non-core brands, we are updating the previously provided outlook for revenues for fiscal 2017, and reconfirming the previously provided estimates for adjusted earnings per share and adjusted free cash flow. We are reducing our revenue outlook by $\$ 17.0$ million to reflect the impact of the sale of the three brands. Our outlook for revenue growth is now in the range of $4.0 \%$ to $6.0 \%$ for the fiscal year, including the impact of currency fluctuations. We do not anticipate any impact from the sale on our previously provided outlook for adjusted earnings per share for the fiscal year, which continues to be in the range of $\$ 2.30$ to $\$ 2.36$. Our previously provided outlook for adjusted free cash flow of $\$ 185$ million also remains unchanged," Mr. Lombardi said.

## Q1 Conference Call \& Accompanying Slide Presentation

The Company will host a conference call to review its first quarter results on August 4, 2016 at $8: 30 \mathrm{am}$ EDT. The toll-free dial-in numbers are 877-784-9650 within North America and 530-379-4717 outside of North America. The conference ID is 43058034 . The Company will provide a live

Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://prestigebrands.com. The slide presentation can be accessed just before the call from the Investor Relations page of the website by clicking on Webcasts and Presentations. Telephonic replays will be available for two weeks following the completion of the call and can be accessed at 855-859-2056 within North America and at 404-537-3406 from outside North America. The conference ID is 43058034.

## Non-GAAP Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the "About Non-GAAP Financial Measures" section at the end of this earnings release.

## About Prestige Brands Holdings, Inc.

The Company markets and distributes brand name over-the-counter and household cleaning products throughout the U.S and Canada, Australia and in certain other international markets. The Company's brands include Monistat $®$ women's health products, Nix $®$ lice treatment, Chloraseptic $®$ sore throat treatments, Clear Eyes® eye care products, Compound W® wart treatments, The Doctor's $®$ NightGuard $®$ dental protector, Little Remedies $®$ pediatric products, Efferdent $®$ denture care products, Luden's $®$ throat drops, Dramamine $®$ motion sickness treatment, $B C ®$ and Goody's $®$ pain relievers, Beano $®$ gas prevention, Debrox $®$ earwax remover, and Gaviscon $®$ antacid in Canada. Visit the Company's website at www.prestigebrands.com.

## Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "assumptions," "target," "guidance," "strategy," "outlook," "plans," "projection," "may," "will," "would," "expect," "intend," "estimate," "anticipate," "believe", "potential," or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's expectations regarding future operating results including revenues, adjusted earnings per share and adjusted free cash flow, and the Company's portfolio mix. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of our advertising and promotional initiatives, the severity of the cold and flu season, general economic and business conditions, fluctuating foreign exchange rates, consumer trends, competition in our industry, the ability of our third party manufacturers and suppliers to meet demand for our products, and introductions of new products. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2016 and other periodic reports filed with the Securities and Exchange Commission.

## Prestige Brands Holdings, Inc. <br> Consolidated Statements of Operations and Comprehensive Income

## (Unaudited)

## (In thousands, except per share data)

Three Months Ended June 30,

## Revenues

| Net sales | $\$ 208,770$ | $\$ 191,287$ |
| :--- | :--- | :--- |
| Other revenues | 805 | 845 |
| Total revenues | 209,575 | 192,132 |

## Cost of Sales

| Cost of sales (exclusive of depreciation shown below) | 87,984 | 79,896 |
| :--- | :--- | :--- |
| Gross profit | 121,591 | 112,236 |

## Operating Expenses

| Advertising and promotion | 27,635 | 26,422 |
| :--- | :--- | :--- |
| General and administrative | 19,457 | 17,589 |
| Depreciation and amortization | 6,832 | 5,720 |
| Loss on sale of assets | 55,453 | - |
| Total operating expenses | 109,377 | 49,731 |
| Operating income | 12,214 | 62,505 |

## Other (income) expense

| Interest income | (57 | ) | $(27$ |
| :--- | :--- | :--- | :--- |
| Interest expense | 21,184 | 21,911 |  |
| Loss on extinguishment of debt | - | 451 |  |
| Total other expense | 21,127 | 22,335 |  |
| (Loss) income before income taxes | $(8,913$ | 40,170 |  |

(Benefit) provision for income taxes
Net (loss) income
(Loss) earnings per share:
Basic
Diluted

Weighted average shares outstanding:
Basic
Diluted

Comprehensive (loss) income, net of tax
Currency translation adjustments
Total other comprehensive loss
Comprehensive (loss) income

Prestige Brands Holdings, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands)

## Assets

Current assets
Cash and cash equivalents
Accounts receivable, net
Inventories
Deferred income tax assets
Prepaid expenses and other current assets
Assets held for sale
Total current assets

Property and equipment, net
Goodwill
Intangible assets, net
Other long-term assets
Total Assets

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable
Other accrued liabilities
Total current liabilities

Long-term debt
Principal amount
Less unamortized debt costs
Long-term debt, net

Deferred income tax liabilities
Other long-term liabilities
Total Liabilities

## Stockholders' Equity

Preferred stock - $\$ 0.01$ par value
Authorized - 5,000 shares
Issued and outstanding - None

| $(3,382$ | $)$ | 13,997 |  |
| :--- | :--- | :--- | :--- |
| $\$$ | $(5,531)$ | $\$$ | 26,173 |


| $\$$ | $(0.10$ | $)$ | $\$$ | 0.50 |
| :--- | :--- | :--- | :--- | :--- |
| $\$$ | $(0.10$ | $)$ | $\$$ | 0.49 |


| 52,881 | 52,548 |
| :--- | :--- |
| 52,881 | 52,958 |


| $(5,824$ | $)$ | $(405$ |  |
| :--- | :--- | :--- | :--- |
| $(5,824$ | $)$ | $(405$ |  |
| $\$$ | $(11,355)$ | $\$$ | 25,768 |

Common stock - \$0.01 par value
Authorized - 250,000 shares
Issued - 53,247 shares at June 30, 2016 and 53,066 shares at March 31, 2016
Additional paid-in capital
Treasury stock, at cost - 331 shares at June 30, 2016 and 306 shares at March 31, 2016
Accumulated other comprehensive loss, net of tax
Retained earnings
Total Stockholders' Equity
Total Liabilities and Stockholders' Equity
$\left.\begin{array}{lll}532 & 530 & \\ 451,075 & 445,182 & \\ (6,558 & ) & (5,163 \\ (29,349 & ) & (23,525\end{array}\right)$

## Prestige Brands Holdings, Inc.

## Consolidated Statements of Cash Flows

(Unaudited)


Prestige Brands Holdings, Inc.
Consolidated Statements of Operations
(Unaudited)

|  | Three Months Ended June 30, 2016 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| (In thousands) | North <br> American <br> OTC <br> Healthcare |  | rnational <br> althcare | Household Cleaning | Consolidated |
| Gross segment revenues | \$ 173,301 | \$ | 15,800 | \$ 20,890 | \$ 209,991 |
| Elimination of intersegment revenues | (1,221 ) |  |  | - | (1,221 ) |
| Third-party segment revenues | 172,080 |  | 800 | 20,890 | 208,770 |
| Other revenues | - | 4 |  | 801 | 805 |
| Total segment revenues | 172,080 |  | 804 | 21,691 | 209,575 |
| Cost of sales | 65,718 |  |  | 16,802 | 87,984 |
| Gross profit | 106,362 |  | 340 | 4,889 | 121,591 |
| Advertising and promotion | 25,040 |  |  | 471 | 27,635 |
| Contribution margin | \$ 81,322 | \$ | 8,216 | \$ 4,418 | 93,956 |
| Other operating expenses* |  |  |  |  | 81,742 |
| Operating income |  |  |  |  | 12,214 |
| Other expense |  |  |  |  | 21,127 |
| Loss before income taxes |  |  |  |  | (8,913 ) |
| Benefit for income taxes |  |  |  |  | (3,382 ) |
| Net loss |  |  |  |  | \$ (5,531 ) |

*Other operating expenses includes a pre-tax loss on sale of assets of $\$ 55.5$ million recognized for assets held for sale related to Pediacare, New Skin and Fiber Choice. These assets and corresponding contribution margin are included within the North American OTC Healthcare segment.

Three Months Ended June 30, 2015

|  | North <br> American <br> OTC <br> Healthcare | International <br> OTC <br> Healthcare | Household <br> Cleaning | Consolidated |
| :--- | :--- | :--- | :--- | :--- | :--- |
| (In thousands) | $\$ 156,339$ | $\$ 14,209$ | $\$ 21,467$ | $\$ 192,015$ |
| Gross segment revenues | $(728$ | - | - | $(728$ |
| Elimination of intersegment revenues | ) |  |  |  |
| Third-party segment revenues | 155,611 | 14,209 | 21,467 | 191,287 |
| Other revenues** | 15 | 25 | 805 | 845 |
| Total segment revenues | 155,626 | 14,234 | 22,272 | 192,132 |
| Cost of sales** | 58,503 | 4,913 | 16,480 | 79,896 |
| Gross profit | 97,123 | 9,321 | 5,792 | 112,236 |
| Advertising and promotion | 23,195 | 2,723 | 504 | 26,422 |
| Contribution margin | $\$ 73,928$ | $\$ 6,598$ | $\$ 5,288$ | 85,814 |
| Other operating expenses |  |  |  | 23,309 |
| Operating income |  |  |  | 62,505 |
| Other expense |  |  |  | 22,335 |
| Income before income taxes |  |  |  | 40,170 |
| Provision for income taxes |  |  |  | 13,997 |
| Net income |  |  |  | $\$ 26,173$ |

**Certain immaterial amounts relating to other revenues and cost of sales were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented.

## About Non-GAAP Financial Measures

We define Non-GAAP Organic Revenues as Total Revenues excluding revenues associated with products acquired or divested in the periods presented. We define Non-GAAP Organic Revenues on a Constant Currency basis as Total Revenues excluding acquisitions and divestitures and the impact of current year foreign exchange rates on total revenues. We define Non-GAAP Adjusted EBITDA as earnings before interest expense (income), income taxes, depreciation and amortization, certain other legal and professional fees, other acquisition-related costs, divestiture costs, costs associated with our CEO transition, loss on sale of assets, and loss on extinguishment of debt. Non-GAAP Adjusted EBITDA Margin is calculated as Non-GAAP Adjusted EBITDA divided by GAAP Total Revenues. We define Non-GAAP Adjusted General and Administrative expenses as General and Administrative expenses minus certain other legal and professional fees, acquisition and other integration costs, divestiture costs, and costs associated with our CEO transition. Non-GAAP Adjusted General and Administrative expense percentage is calculated based on Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues. We define Non-GAAP Adjusted Net Income as Net Income before
certain other legal and professional fees, other acquisition and integration-related costs, divestiture costs, costs associated with our CEO transition, accelerated amortization of debt origination costs, loss on sale of assets, loss on extinguishment of debt, and the applicable tax impacts associated with these items and other non-deductible items. Non-GAAP Adjusted EPS is calculated based on Non-GAAP Adjusted Net Income, divided by the weighted average number of common and potential common shares outstanding during the period. We define Non-GAAP Free Cash Flow as net cash provided by operating activities less cash paid for capital expenditures. We define Non-GAAP Adjusted Free Cash Flow as net cash provided by operating activities less purchases of property and equipment plus integration, transition, and other payments associated with acquisitions and divestitures. Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow may not be comparable to similarly titled measures reported by other companies.

We are presenting Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow, because they provide additional ways to view our operation when considered with both our GAAP results and the reconciliation to net (loss) income and net cash provided by operating activities, respectively, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Each of Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow is presented solely as a supplemental disclosure because (i) we believe it is a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow internally to evaluate the performance of our personnel and also as a benchmark to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow have limitations, and you should not consider these measures in isolation from or as an alternative to GAAP measures such as Total Revenues, General and Administrative expense, Operating income, Net (loss) income, and Net cash flow provided by operating activities, or cash flow statement data prepared in accordance with GAAP, or as a measure of profitability or liquidity.

The following tables set forth the reconciliation of Non-GAAP Organic Revenues, Non-GAAP Organic Revenues on a Constant Currency basis, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense percentage, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted EPS, Non-GAAP Free Cash Flow, and Non-GAAP Adjusted Free Cash Flow, all of which are non-GAAP financial measures, to GAAP Total Revenues, GAAP General and Administrative Expense, GAAP Net (Loss) Income, GAAP Diluted EPS and GAAP Net cash provided by operating activities, our most directly comparable financial measures presented in accordance with GAAP.

Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and Non-GAAP Organic Revenues on a Constant Currency basis and related growth percentages:

## (In thousands) <br> GAAP Total Revenues

| Three Months <br> Ended June 30, <br> 2016 | 2015 |
| :--- | :--- |

Adjustments:
$\left.\begin{array}{llll}\text { DenTek revenues }{ }^{(1)} & (16,627 & ) & - \\ \text { Total adjustments } & (16,627 & ) & - \\ \text { Non-GAAP Organic Revenues } & 192,948 & & 192,132 \\ \text { Organic Revenue Growth (Decline) } & 0.4 & \% & \\ \text { Impact of foreign currency exchange rates (2) } & & & (829\end{array}\right)$
(1) Revenue adjustments relate to our North American and International OTC Healthcare segment
(2) Foreign currency exchange rate adjustments relate to all segments

Reconciliation of GAAP General and Administrative Expense to Non-GAAP Adjusted General and Administrative Expense and related Non-GAAP Adjusted General and Administrative Expense percentage:
Three Months Ended June 30,
$2016 \quad 2015$

## (In thousands)

GAAP General and Administrative Expense
\$ 19,457 \$ 17,589

Adjustments:

| Costs associated with CEO transition | - | 1,406 |
| :--- | :--- | :--- |
| Legal and professional fees associated with acquisitions and divestitures | 484 | - |
| Integration, transition and other costs associated with acquisitions and divestitures | 1,641 | - |
| Total adjustments | 2,125 | 1,406 |
| Non-GAAP Adjusted General and Administrative Expense | $\$ 17,332$ | $\$ 16,183$ |
| Non-GAAP Adjusted General and Administrative Expense Percentage | 8.3 | $\%$ |

Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:

|  | Three Months Ended June 30, |  |
| :---: | :---: | :---: |
| (In thousands) |  |  |
| GAAP Net (Loss) Income | \$ (5,531) | \$ 26,173 |
| Interest expense, net | 21,127 | 21,884 |
| (Benefit) provision for income taxes | (3,382 | 13,997 |
| Depreciation and amortization | 6,832 | 5,720 |
| Non-GAAP EBITDA: | 19,046 | 67,774 |
| Adjustments: |  |  |
| Costs associated with CEO transition (1) | - | 1,406 |
| Legal and professional fees associated with acquisitions and divestitures ${ }^{(1)}$ | 484 | - |
| Integration, transition and other costs associated with acquisitions and divestitures ${ }^{(1)}$ | 1,641 | - |
| Loss on extinguishment of debt | - | 451 |
| Loss on sale of assets | 55,453 | - |
| Total adjustments | 57,578 | 1,857 |
| Non-GAAP Adjusted EBITDA | \$ 76,624 | \$ 69,631 |
| Non-GAAP Adjusted EBITDA Margin | 36.6 \% | 36.2 \% |

## Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted Net Income and related Adjusted Earnings Per Share:

| Three Months Ended June 30, |  |  |  |
| :---: | :---: | :---: | :---: |
|  | 2016 |  | 2015 |
| 2016 | Adjusted | 2015 | Adjusted |
|  | EPS |  | EPS |

## (In thousands)

GAAP Net (Loss) Income
Adjustments:

| Costs associated with CEO transition ${ }^{(1)}$ | - | - | 1,406 | 0.03 |
| :---: | :---: | :---: | :---: | :---: |
| Legal and professional fees associated with acquisitions and divestitures ${ }^{(1)}$ | 484 | 0.01 | - | - |
| Integration, transition and other costs associated with acquisitions and divestitures ${ }^{(1)}$ | 1,641 | 0.03 | - | - |
| Loss on extinguishment of debt | - | - | 451 | 0.01 |
| Loss on sale of assets | 55,453 | 1.04 | - | - |
| Tax impact of adjustments | (20,658 ) | (0.39 | (657 ) | (0.01 |
| Total adjustments | 36,920 | 0.69 | 1,200 | 0.03 |
| Non-GAAP Adjusted Net Income and Adjusted EPS | \$ 31,389 | \$ 0.59 | \$ 27,373 | \$ 0.52 |

(1) Adjustments relate to G\&A expenses

Reconciliation of GAAP Net (Loss) Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow:

```
Three Months Ended June 30, 2016

\section*{(In thousands)}
GAAP Net (Loss) Income
\$ (5,531 ) \$ 26,173

Adjustments:
\begin{tabular}{|c|c|c|}
\hline Adjustments to reconcile net (loss) income to net cash provided by operating activities as shown in the Statement of Cash Flows & 56,796 & 22,856 \\
\hline Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows & (514 ) & (5,508 \\
\hline Total adjustments & 56,282 & 17,348 \\
\hline GAAP Net cash provided by operating activities & 50,751 & 43,521 \\
\hline Purchases of property and equipment & (895 ) & (780 \\
\hline Non-GAAP Free Cash Flow & 49,856 & 42,741 \\
\hline Integration, transition and other payments associated with acquisitions and divestitures & 331 & - \\
\hline Adjusted Non-GAAP Free Cash Flow & \$ 50,187 & \$ 42,741 \\
\hline
\end{tabular}

Outlook for Fiscal Year 2017:
Reconciliation of Projected GAAP EPS to Projected Non-GAAP Adjusted EPS:
\begin{tabular}{lllll} 
& \multicolumn{3}{c}{2017 Projected EPS } \\
& Low & \multicolumn{2}{l}{ High } \\
& \(\$\) & 1.55 & \(\$\) & 1.61 \\
Projected FY'17 GAAP EPS & & & & \\
Adjustments: & 0.08 & 0.08 & \\
Costs associated with DenTek integration & 0.67 & 0.67 & \\
Loss on sale of assets & 0.75 & 0.75 & \\
Total Adjustments & \(\$\) & 2.30 & \(\$\) & 2.36
\end{tabular}

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Adjusted Free Cash Flow:

2017
Projected
Free Cash
Flow

\section*{(In millions)}

Projected FY'17 GAAP Net cash provided by operating activities
Additions to property and equipment for cash
Projected Non-GAAP Free Cash Flow
Payments associated with acquisitions
Adjusted Non-GAAP Projected Free Cash Flow \$ 185```

